Shares of Pfizer Inc. PFE advanced 1.03% to $26.49 Thursday, on what proved to be an all-around rough trading session for the ...

Shares of Pfizer Inc. PFE slid 1.46% to $26.41 Tuesday, on what proved to be an all-around positive trading session for the ...

While presenting at the JP Morgan Healthcare Conference, Pfizer Inc. (NYSE:PFE) Albert Bourla, Chairman and CEO, said, “I ...

Pfizer Inc. sold about 700 million shares in Haleon Plc, further paring its stake in the maker of Sensodyne toothpaste.Most ...

We recently published an article titled Jim Cramer Discussed These 21 Stocks As Bond Yields Soared. In this article, we are ...

We recently compiled a list of the 12 Most Reliable Dividend Stocks To Buy According to Hedge Funds. In this article, we are ...

Pfizer is expected to rebound in 2025 with growth stabilized and dividend growth to continue. Learn why PFE stock is a Buy.

Analyst Evan Seigerman from BMO Capital maintained a Buy rating on Pfizer (PFE – Research Report) and keeping the price target at $36.00.Stay ...

A federal appeals court revived a lawsuit on Friday challenging Pfizer Inc.‘s fellowship program aimed at building a diverse ...

Citi analyst Geoff Meacham maintained a Hold rating on Pfizer (PFE – Research Report) today. The company’s shares closed yesterday at ...

A recent patient-led case series highlights the potential benefits of extended courses of Pfizer Inc's (NYSE:PFE) Paxlovid ...

Pfizer Inc. (NYSE:PFE) released topline results from its Phase 3 CREST trial evaluating sasanlimab, an investigational ...